The goal of this multicentre clinical pilot study is to investigate the feasibility of the addition of Ho-166 radioembolization to chemotherapy in patients with liver metastastic breast cancer. Participants will receive a mapping angiography and Ho-166 radioembolization. Chemotherapy will be stopped 2-5 prior to radioembolization and continuation of chemotherapy will be evaluated at 2 weeks post-radioembolization.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
13
The intervention comprises two steps. Initially, the patient will undergo mapping angiography and a Ho-166 scout dose. If deemed eligible, the patient will proceed to 166-Ho radioembolization.
University Hospital Leuven
Leuven, Vlaams-Brabant, Belgium
NOT_YET_RECRUITINGNetherlands Cancer Institute
Amsterdam, North Holland, Netherlands
RECRUITINGFeasibility
The percentage of patients were radioembolization and systemic chemotherapy is safely feasible. Safety is defined as percentage of 90 day post-radioembolization (CTCAE/SIR grade 3 or higher) which lead discontinuation of the current systemic chemotherapy. Time to re-start chemotherapy after intervention in days will be collected.
Time frame: Up to 3 months after intervention
Lesion- and patient-based response
Radiological response on contrast-enhanced CT and MRI measured by RECIST
Time frame: Up to 3 months after intervention
Overall toxicity associated with study intervention
Graded by CTCAE/SIR grade
Time frame: Up to 3 months after intervention
Quality of Life during study
Obtained by EORTC QLQ-C30 questionnaire
Time frame: From start inclusion to 3 months after intervention
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.